The Latest

  • COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Board of Directors
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
  • Our Clinical Trials
    • CNP-106 Myasthenia Gravis
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

Leadership

Bringing together extensive expertise in clinical development, scientific research, manufacturing and business, COUR’s leadership team embodies the company’s mission to deliver life-changing therapies designed to reprogram the immune system.

Dannielle Appelhans
Dannielle Appelhans Featured

Dannielle Appelhans

President & CEO

Dannielle Appelhans LinkedIn Profile
Paul M. Peloso, MD
Paul M. Peloso, MD Featured

Paul M. Peloso, MD

Chief Medical Officer

Paul M. Peloso, MD LinkedIn Profile
Brian C. Bock
Brian C. Bock Featured

Brian C. Bock

Chief Financial Officer

Brian C. Bock LinkedIn Profile
Sarah Longoria
Sarah Longoria Featured

Sarah Longoria

Chief People Officer

Sarah Longoria LinkedIn Profile
Adam Elhofy, PHD
Adam Elhofy, PHD Featured

Adam Elhofy, PHD

VP, Research

Adam Elhofy, PHD LinkedIn Profile
Robert Hodge
Robert Hodge Featured

Robert Hodge

VP, Technical Development

Robert Hodge LinkedIn Profile
Lori Jester
Lori Jester Featured

Lori Jester

VP, Manufacturing and Supply Chain

Lori Jester LinkedIn Profile
Stan Russell 
Stan Russell  Featured

Stan Russell 

VP, Quality

Stan Russell  LinkedIn Profile
Karthi Natarajan 
Karthi Natarajan  Featured

Karthi Natarajan 

Head of Clinical Operations

Karthi Natarajan  LinkedIn Profile
Tony Mitchell
Tony Mitchell Featured

Tony Mitchell

VP, Controller

Tony Mitchell LinkedIn Profile

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2025

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top